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Abstract
AIM: To systematically review the survival outcomes 
relating to extramural venous invasion in rectal cancer.
METHODS: A systematic review was conducted using 
PRISMA guidelines. An electronic search was carried 
out using MEDLINE, EMBASE, CINAHL, Cochrane library 
databases, Google scholar and PubMed until October 
2014. Search terms were used in combination to yield 
articles on extramural venous invasion in rectal cancer. 
Outcome measures included prevalence and 5-year 
survival rates. These were graphically displayed using 
Forest plots. Statistical analysis of the data was carried 
out.
RESULTS: Fourteen studies reported the prevalence 
of extramural venous invasion (EMVI) positive patients. 
Prevalence ranged from 9%-61%. The pooled 
prevalence of EMVI positivity was 26% [Random 
effects: Event rate 0.26 (0.18, 0.36)]. Most studies 
showed that EMVI related to worse oncological 
outcomes. The pooled overall survival was 39.5% 
[Random effects: Event rate 0.395 (0.29, 0.51)].
CONCLUSION: Historically, there has been huge 
variation in the prevalence of EMVI through inconsistent 
reporting. However the presence of EMVI clearly 
leads to worse survival outcomes. As detection rates 
become more consistent, EMVI may be considered as 
part of risk-stratification in rectal cancer. Standardised 
histopathological definitions and the use of magnetic 
resonance imaging to identify EMVI will improve 
detection rates in the future.
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Core tip: Extramural venous invasion (EMVI) has 
been shown to be an adverse risk factor in rectal 
cancer. Historical studies have shown a wide range of 
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prevalence which has made survival risk difficult to 
interpret. This has been due to lack of standardised 
detection methods. As these methods improve, we 
are more likely to be able to identify those patients 
with evidence of EMVI and thus offer patients optimal 
treatment.
Chand M, Siddiqui MRS, Swift I, Brown G. Systematic review 
of prognostic importance of extramural venous invasion in rectal 
cancer. World J Gastroenterol 2016; 22(4): 1721-1726  Available 
from: URL: http://www.wjgnet.com/1007-9327/full/v22/i4/1721.
htm  dOI: http://dx.doi.org/10.3748/wjg.v22.i4.1721
INTRODUCTION
Venous invasion is considered a prognostic factor in 
rectal cancer[1-7] however the exact effect on survival 
outcomes and disease recurrence remains unknown. 
The current nomenclature refers to extramural venous 
invasion (EMVI) and specifically describes tumour cells 
within the veins outside the muscularis propria of the 
bowel wall[8]. This distinction from other descriptions 
of venous or vascular invasion is helpful in the modern 
management of rectal cancer where risk of recurrence 
needs to be accurately defined for individual patients, 
to determine whether they would benefit from neo-
adjuvant and adjuvant therapies. 
The existing literature generally examines venous 
invasion based on pathology specimens and combine 
colon and rectal cancer. There are only a limited 
number of reports focusing on rectal cancer with clear 
methods and definitions used for identification of EMVI. 
As a result there is a large variation in reporting EMVI 
between pathologists[9,10]. Furthermore, the reliance 
on pathology for identification of EMVI particularly 
after neoadjuvant treatment (CRT) may lead to under-
detection[11]. 
More recently, magnetic resonance imaging (MRI) 
has been shown to accurately detect EMVI before 
and after CRT and identify cases which are missed 
on routine pathological assessment[11]. These incon-
sistencies in the definition and specific histological 
methods applied have led to challenging interpretation 
of the true incidence and risk associated with EMVI; 
leading to its lack of mandatory consideration for 
oncological treatment. If EMVI is shown to have 
prognostic implications but is being under-detected by 
traditional histopathological methods alternatives such 
as MRI may be considered to avoid the risk of disease 
recurrence.
The aim of this review is to critically examine the 
evidence for the prognostic importance of venous 
invasion; specifically EMVI on histopathology, on the 
survival outcomes of rectal cancer.
MATERIALS AND METHODS
An electronic search was carried out using MEDLINE 
(1965-2014), EMBASE (1980-2014), CINAHL (1982-2014) 
and the Cochrane library databases. Google scholar 
and PubMed were used to search articles prior to 1965. 
Medical subject heading terms and keywords were 
used: “rectal cancer”; “venous invasion”; “vascular 
invasion”; “extramural”; and “EMVI”. The “related 
articles” function was used to broaden the search and 
all abstracts, studies, and citations retrieved were 
scanned for subject relevance. The latest date of this 
search was October 2014. All potentially relevant 
manuscripts were retrieved and evaluated for inclusion. 
Reference lists of all relevant publications were hand-
searched for additional studies, and cross referenced 
until no further relevant publications were identified. 
Study methodology was carried out in accordance 
with the “Preferred Reporting for Systematic Reviews 
and Meta-Analyses” guidelines. We included all studies 
in English reporting on outcomes of venous invasion 
or EMVI in curative rectal cancer. Adult patients 
over the age of 18 were included. Where multiple 
studies describing the same patient population were 
identified, the most recent publication was used. Case 
reports were excluded. Studies of colorectal cancer 
were included where data for rectal cancer could be 
extracted. We included studies if they reported on 
outcomes such as disease recurrence and overall 
survival. Quality assessment of eligible studies was 
carried out by two independent reviewers.
Pooling of prevalence rates was performed using 
Comprehensive Meta-Analysis[12] and forest plots were 
used as a graphical display.
RESULTS
Literature search and description of studies
Three hundred and sixty-four publications were initially 
identified with potential relevance (figure 1). Thirty-
two articles included patients who did not undergo 
surgery; 30 articles described techniques only; 25 
articles were case reports; 24 articles described 
venous invasion outside the context of cancer. further 
screening identified 14 studies published between 
1935 and 2014 which were included in this review. 
This is shown in Table 1.
Study characteristics
A total of 7262 patients in 14 studies were involved in 
this review. The patient cohort spanned 1938-2006. 
Six studies were retrospective. Only 6 studies commented 
on number of pathologists and blinding status[2,6,13-16]. 
There was clinical heterogeneity in the stains used, the 
common ones being used were H + E, Gieson’s, elastin 
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Records Identified through Medline, 
Embase, Cinhal searching
n  = 426
Records after duplicates removed
n  = 378
Records screened
n  = 367
Full text articles assessed for 
eligibility
n  = 125
Studies included in qualitative 
synthesis 
n  = 14
Studies included in quantitative 
synthesis 
(meta-analysis)
n  = 14
Records excluded
n  = 11
Full text articles excluded with 
reasons
n  = 111
Unrelated articles
Technique articles
Commentary or letter articles
Case reports
Venous invasion outside context of 
EMVI
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Figure 1  Flowchart showing search strategy for systematic review. EMVI: Extramural venous invasion.
Table 1  The prevalence of vascular invasion in rectal cancer
Author Year No. 
patients
Study design No. of 
pathologists, 
blinding
Stain Tumour
site
Elastin 
stain
No. EMVI 
+ve pts
Prev VI 
+ve
EMVI +ve 
5 yr survival
Independent 
prognosticator
Brown et al[29] 1938   170 Retrospective Unspecified H + E Rectum Yes 104    61% No 5 yr data No comment
Dukes et al[30] 1941   689 Prospective Unspecified No stain Rectum No 107    17% No 5 yr data No comment
Seefeld et al[13] 1943   100 Prospective 1, blinded H + E, Gieson’s Rectum Yes   20    20% 5% No comment
Madison 
et al[31]
1954     42 Prospective Unspecified Brominol, H + E, 
Gieson’s
Rectum Yes   19    43% No 5 yr data No comment
Carroll[17] 1963 1996 Retrospective Unspecified H + E Rectum No 240 11.8% 36% No comment
Khankhanian 
et al[32]
1977   143 Retrospective Unspecified Not stated Rectum No   70 19% (BVI + 
LVI)
Data not 
usable
EMVI is +ve 
IPS
Talbot et al[6] 1980   706 Prospective 2, blinded H + E, elastin Rectum Yes 366    52% 33% 
EMVI+ve
No comment
Rich et al[15] 1983   142 Prospective 1, blinded H + E RS/
Rectum
No   23    17% No 5 yr data No comment
Freedman 
et al[4]
1984   494 Retrospective Unspecified No comment Rectum Yes   89    36% 31% 
EMVI+ve
No comment
Jass et al[16] 1986   447 Prospective 1, blinded H + E Rectum No 116    26% 
(extramural 
only)
41% 
EMVI+ve
EMVI - No IPS
Sasaki et al[33] 1987   774 Retrospective Unspecified H + E Rectum No 163    21% 
(extramural 
only)
No 5 yr data No comment
Minsky et al[14] 1988   168 Retrospective 1, blinded H + E, elastin RS/
Rectum
Yes   81    48% 33% 
EMVI+ve
EMVI - No IPS
Harrison et al[2] 1994   348 Retrospective 2, blinded H + E, elastin Rectum Yes   74 21.2% 21% 
EMVI+ve
EMVI has IPS
Ptok et al[18] 2006 1043 Retrospective Unspecified Not state Rectum No   75      9% 80.7% LVI 
+ve
EMVI - No IPS
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detection rates. The prevalence ranges from 9%-61% 
reflecting the inconsistent nature of recognition and 
detection. The overall prevalence is around 25% which 
is consistent with guidance from the Royal College of 
Pathologists. 
The present study has shown that venous invasion 
generally, and EMVI more specifically, is associated 
with worse survival outcomes. Despite this, EMVI is not 
considered a mandatory factor for the use of adjuvant 
treatment. Indeed the current position on EMVI is 
variable and has been recently investigated[19]. Many 
clinicians rely on the EMVI status to make decisions 
on treatment and it has become a mandatory part 
of the pathology reporting dataset in the United 
Kingdom. The reasons behind this variability on 
behalf of clinicians are unknown. This may be due 
to inconsistent detection rates shown above or may 
be that it is rare to find EMVI without the association 
of more traditional adverse features such as nodal 
disease or increased T-stage. However, the evolution 
of rectal cancer management may lead to a change in 
attitude towards EMVI if a more selective approach is 
taken to neoadjuvant treatment in the light of clinical 
trial evidence. For example, the universal policy of 
irradiating all T3 tumours or any tumour that has 
and Brominol. All the studies we included examined 
rectal tumours however 2 papers also incorporated 
rectosigmoid tumours[14,15].
Prevalence
Prevalence of EMVI positive patients ranged from 
9%-61% in the studies. The pooled overall prevalence 
from fourteen studies was 26% [Random effects: 
Event rate 0.26 (0.18, 0.36), z = -4.3, Q = 787, I2 = 
98%] (figure 2).
Survival outcomes in the presence of venous invasion
Seven studies reported on 5 year survival rates in 
patients with EMVI positive histology[4,6,13,14,16-18]. The 
pooled overall survival was 39.5% [Random effects: 
Event rate 0.395 (0.29, 0.51), z = -1.9, Q = 58.06, I2 
= 90%] (figure 3).
DISCUSSION
The results of the present study have shown an asso-
ciation between venous invasion and poor prognosis. 
Patients that demonstrate evidence of venous invasion 
have worse overall survival. However the most 
striking finding is the variation in histopathological 
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Study name Statistics for each study Event rate and 95%CI
Event rate Lower limit Upper limit Z -value
Brown and Warren, 1938 0.612 0.537 0.682    2.890
Dukes and Bussey, 1941 0.170 0.144 0.200 -15.640
Seefeld and Bargen, 1943 0.200 0.133 0.290   -5.545
Madison et al , 1954 0.429 0.289 0.580   -0.923
Carroll, 1963 0.118 0.104 0.133 -29.000
Khankhanian et al , 1977 0.189 0.133 0.261   -6.822
Talbot et al , 1980 0.520 0.483 0.557    1.054
Rich et al , 1983 0.169 0.116 0.240   -7.112
Freedman et al , 1984 0.360 0.319 0.404   -6.125
Jass et al , 1986 0.260 0.221 0.302   -9.718
Sasaki et al , 1987 0.211 0.183 0.241 -14.989
Minsky et al , 1988 0.482 0.408 0.558   -0.463
Harrison et al , 1994 0.213 0.173 0.259   -9.992
Ptok et al , 2006 0.090 0.074 0.109 -21.383
0.262 0.182 0.362   -4.342
-1.00     -0.50      0.00      0.50      1.00
                                 Prevalence
Figure 2  Forest plot for prevalence of extramural venous invasion. 
Study name Statistics for each study Event rate and 95%CI
Event rate Lower limit Upper limit Z -value
Seefeld and Bargen, 1943 0.050 0.007 0.282 -2.870
Carroll, 1963 0.362 0.303 0.425 -4.184
Talbot et al , 1980 0.330 0.283 0.379 -6.390
Freedman et al , 1984 0.309 0.245 0.381 -4.962
Jass et al , 1986 0.414 0.328 0.505 -1.848
Minsky et al , 1988 0.333 0.240 0.442 -2.941
0.342 0.299 0.388 -6.507
-0.50    -0.25    0.00    0.25     0.50
                           Survival rate
Figure 3  Forest plot for 5-year overall survival in extramural venous invasion positive rectal cancer.
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local nodal disease may be over-treating a proportion 
of patients. There is accumulating evidence that not 
all T3 tumours behave the same and that it is depth 
of penetration through the mesorectum (T3 sub-
stage) that is prognostic[20,21]. Further, in the presence 
of optimal TME surgery nodal disease may not be 
prognostic for local recurrence[22]. In these situations 
whereby early T3 tumours or those with N1 disease 
may not benefit from neoadjuvant chemoradiotherapy, 
it may be EMVI which tips the balance towards pre-
operative treatment. Another consideration is that 
stage Ⅱ tumours are a heterogenous group and it 
is those which demonstrate EMVI that have a much 
higher risk of disease recurrence and may ultimately 
benefit from adjuvant chemotherapy[23].
The more consistent detection rates, found in 
more recent reports usually use the terminology of 
“extramural venous invasion”. Messenger et al[24] 
have offered suggestions which may help pathologists 
improve detection rates - the use of elastin stains 
to identify cases where there is uncertainty; and 
to reference imaging studies such as MRI to guide 
sampling. 
MRI can accurately identify EMVI both before and 
after CRT[8,25,26]. It has also been shown to detect 
cases of EMVI which have been “missed” on routine 
pathology[25].  A further benefit of MRI is that it is 
able to visualise the entire rectum in-situ whereas the 
analysis of a small sample of the tumour is dependent 
on macroscopic assessment by the pathologist in the 
first instance, to ensure a representative area has 
been evaluated.
Current multicentre studies such as BACCHUS 
(Bevacizumab And Combination Chemotherapy in 
rectal cancer Until Surgery)[27] and MARVEL (Molecular 
And Radiological EValuation of Extramural venous 
invasion in RectaL Cancer)[28], may help in resolving 
some of these issues and future results will be highly 
anticipated.
In conclusion, the presence of EMVI leads to 
worse survival outcomes. As detection rates become 
more consistent, EMVI may be considered as part 
of risk-stratification in rectal cancer. Standardised 
histopathological definitions and MRI may improve 
detection rates in the future.
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